Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits

Abstract

PP1M was associated with higher antipsychotic adherence and persistence, and similar total costs versus OAA.